Australia markets closed

ABBV Jun 2023 180.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.5900-0.8600 (-35.10%)
At close: 10:33AM EDT
Full screen
Previous close2.4500
Expiry date2023-06-16
Day's range1.5900 - 1.5900
Contract rangeN/A
Open interest1.36k
  • Motley Fool

    Here's Why This Dividend King Is a Buy

    Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.

  • Motley Fool

    Where Will AbbVie Be in 3 Years?

    In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.

  • PR Newswire

    AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022

    AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).